ABSTRACT. Previous studies have shown that the dilating effect of nitric oxide (NO) on the fetal ductus arteriosus (DA) is age dependent and more marked in the premature stages in rats, but the factors that mediate this effect are poorly understood. The purpose of this study is to determine the changes in the expression of NO synthase (NOS) mRNA in the fetal DA and to examine the effect of an 11--hydroxylase inhibitor of corticosterone synthesis, namely, metyrapone, on NOS expression. NOS 3 mRNA expression was observed in 17.5-day-old rat fetuses; thereafter, its level significantly increased and reached its peak on day 19.5 and then decreased until the end of the gestation period (day 21.5). To inhibit corticosterone synthesis, a constant infusion of metyrapone was administered to rats; this significantly decreased the fetal plasma corticosterone concentration as well as NOS 3 mRNA expression in the DA in a time-dependent manner. These results indicate that NO is generated by NOS 3 in the DA and that the age-dependant expression of NOS 3 in the premature DA is attributable to corticosterone-associated activity.
The ductus arteriosus (DA) is a fetal vascular shunt that connects the main pulmonary artery (PA) to the descending aorta. In utero, the DA conducts > 90% of the right ventricular output to the aorta, bypassing the fetal pulmonary system. When respiration begins after birth, the DA rapidly closes and transforms into a fibrous cord. The relaxed state of the fetal DA was previously considered to be a passive process; however, it is now clear that vasodilating stimuli are required to maintain the DA in a dilated state in utero [25] . Previous studies have shown that dilator prostaglandins (PGs), especially PGE 2 , play major roles in maintaining DA patency in utero [2, 3, 5, 15] . However, the dilating effect of PGs was not observed during the preterm stages in rats [18, 26] and humans [17, 29] .
Nitric oxide (NO) has emerged as a major determinant of vascular tone under both physiologic and pathophysiologic conditions [20] . In mammals, three isoforms of nitric oxide synthase (NOS), namely, NOS 1 (neuronal NOS, nNOS), NOS 2 (inducible NOS, iNOS), and NOS 3 (endothelial NOS, eNOS), have been identified. Recent studies suggest that NO is more important than PGE 2 in the regulation of ductal tone in the preterm stages [4, 19] . Clyman et al. [4] reported increased sensitivity of ductal strips to the dilating effect of NO during the early fetal stage in lambs. Momma and Toyono [19] reported a change in the effect of N G -nitro-L-arginine methyl ester (L-NAME), an NOS inhibitor, which induces stronger DA contraction in preterm rats (day 19) than in term rats (day 21). In addition, we have previously reported that the constrictive effect of L-NAME on the DA depends on the age of the fetus. L-NAME-induced DA constriction was first observed in a 17-day-old fetus, and it was found to increase to a significant extent thereafter. The constriction reached its peak on day 19 and then reduced until the end of the gestation period [26] . The above findings show that NO plays a major role in determining the patency of the DA in the preterm stage (day 19). However, the factors responsible for the age-related effect of NO, particularly in the preterm stage, are poorly understood.
Glucocorticoid levels are known to fluctuate during the developmental period. Cortisol in humans and corticosterone in rats are the main circulating glucocorticoids that participate in different physiological functions such as metabolism, immunity, learning, and reproduction [7, 11, 14, 24] . In rats, fetal plasma corticosterone is first detected on day 17 [6] ; its level peaks on day 19 and then decreases until the end of the gestation period [8] . Corticosterone induces lung maturation by binding to glucocorticoid receptors [31] , and is therefore thought to be associated with developmental maturation of the DA. On the basis of the above results, we hypothesized that corticosterone affects NOS expression, and that this effect is possibly age dependent. The present study was carried out to determine the chronology of changes in NOS mRNA expression in the fetal DA and the effect of corticosterone on the same by using metyrapone, an inhibitor of corticosterone synthesis.
MATERIALS AND METHODS

Animals:
We used female Wistar rats (Charles River Japan Inc., Tokyo, Japan) aged 10-12 weeks at the time of mating. They were given access to a commercial diet (CE-2; CLEA Japan Inc., Tokyo, Japan) and tap water ad libitum and maintained in a room at 22C  3C with a relative humidity of 55%  10%. Three female rats were housed overnight with a male rat, and the next morning, smears prepared from the vaginal fluid of the 3 rats were examined for the presence of sperm. Noon on the day when sperm was detected in the vaginal smears was designated as day 0.5 of gestation, and the female rats were caged individually thereafter. All the procedures were performed under the guidance of the Committee for Animal Experimentation, Azabu University.
Experiment 1: NOS 3 mRNA expression in the DA and PA was examined from days 17.5 to 21.5 of gestation. Fetuses were collected from the pregnant rats by cesarean operation. Immediately thereafter, fetal DAs and PAs were isolated by sharp dissection under a stereoscopic microscope. From each litter, only the first 3 pups that had not yet drawn their first breath were obtained within 30 min after cervical dissection in the mother rat and were used for the experiment. At each time point, 2-6 DA and PA samples were obtained from rats in 1 or 2 litters and pooled for analysis. To ensure that the sample quantity was sufficient, each pooled sample comprising 2-6 DAs and PAs was considered as a single representative sample.
Experiment 2: To examine the effect of corticosterone on NOS 3 mRNA expression level in the DA, we used metyrapone (Sigma-Aldrich, St. Louis, MO, U.S.A.), a specific 11--hydroxylase inhibitor that selectively inhibits corticosterone synthesis. Metyrapone was dissolved in a vehicle (dimethyl sulfoxide [DMSO] and polyethylene glycol [PEG] 400 mixed in a ratio of 50:50) and infused through osmotic mini-pumps (Alzet model 2001D; Durect Co., Cupertino, CA, U.S.A.) that were implanted into the dorsal area of the mothers at 6, 12, and 24 hr before the rats were sacrificed at 13:00 on day 19 of gestation. We maintained a continuous infusion rate of 26.7 g/min of metyrapone, which is equivalent to 100 mgkg
and is sufficient to inhibit corticosterone synthesis in rats [23, 33] . In the control mothers, only the vehicle was infused under the same treatment conditions. Fetal DAs were obtained during autopsy of the rats delivered via cesarean operation and were used to determine the NOS 3 mRNA expression levels, as described above. To monitor the fetal plasma corticosterone concentration after metyrapone infusion, 3 fetuses from each litter were decapitated, and their blood was collected in heparinized capillary tubes. The blood samples were centrifuged at 4C, and the plasma obtained was stored at -80C until the assay.
Total RNA extraction and quantitative reverse-transcriptase polymerase chain reaction analysis: The pooled DA and PA samples obtained during the period from day 17.5 to day 21.5 of gestation were placed in a lysis buffer and homogenized by repeated passage through a 27-gauge needle. Total RNA was extracted using the SV Total RNA Isolation System (Promega, Madison, WI, U.S.A.), according to the manufacturer's instructions. First-strand cDNA was synthesized from the total RNA (0.2 g) by using reverse transcriptase (RT, SuperScript III; Gibco BBL, Tokyo) and an oligo d(T) 12 primer. The reverse-transcribed cDNA were amplified by PCR with primers specifically designed for Nos 3 (forward: 5'-TGGGCAGCATCAC-C T A C G A -3 ' a n d r e v e r s e : 5 ' -T C C C G A G C A T -CAAATCCT-3', 373 bp). These primers were designed on the basis of the sequence of the rat Nos 3 (accession no. AF085195) gene. The glyceraldehyde-3-phosphate dehydrogenase gene (Gapdh) was used as an internal control to normalize the template concentrations. The primers were synthesized by Texas Genomics Japan (Tokyo, Japan). We quantitatively determined NOS expression according to a previously described method [27] . Briefly, for PCR, 1 l of the reverse-transcribed cDNA was added to a 20-l reaction mixture containing 250 mM of each of the deoxyribonucleotide triphosphates (dNTPs); next, 1 unit of Taq polymerase (rTaq; Takara, Kyoto, Japan) and 0.2 mM of each primer were added. Thermal cycling was performed under the following conditions: 20 cycles for Gapdh and 22 cycles for Nos 3 at 94C for 1 min, at 60C for 1 min, and at 72C for 1 min (GeneAmp 2400; Perkin Elmer Japan, Yokohama, Japan). Because of the abovementioned cycling profiles for the genes, the concentration of the resulting PCR products was proportional to that of the starting cDNA, as determined by a preliminary study. Furthermore, we also checked for genomic DNA contamination by treating all the RNA samples with DNase and by performing PCR without adding reverse transcriptase. The PCR products were separated on a 1.5% agarose gel and stained with SYBR Green I (Takara, Kyoto, Japan). The expression of rat NOS 3 was quantitatively analyzed by scanning the gels stained with SYBR Green I with a Fluoro-Image Analyzer (FLA-2000; Fujifilm, Tokyo). The optical densities of the bands were analyzed using the MacBas image software (MacBas version 2.5; Fujifilm).
Determination of fetal plasma corticosterone levels: The fetal plasma corticosterone concentration was measured using a radioimmunoassay with the rat corticosterone [ 125 I] Biotrak assay system (Amersham Biosciences, Buckinghamshire, UK), according to the manufacturer's instructions. The sensitivity of the assay was determined to be 0.06 ng/ml. Radioactivity was determined using a gamma scintillation counter. The standard curve was prepared in duplicates; in addition, all the samples in a single assay were run in duplicates to avoid interassay variation.
Data analysis: The results are expressed as mean (standard error mean, SEM). The differences among the groups of fetuses were assessed using analysis of variance (ANOVA). If a significant difference was found among the groups, then Scheffe's test was applied to assess this difference. A p value less than 0.05 was considered significant.
RESULTS
NOS 3 mRNA expression in the DA and PA at various stages of fetal development: NOS 3 mRNA expression was observed in the DA on day 17.5 of gestation; thereafter, its level significantly increased and reached peak levels on day 19.5 and then gradually decreased until the end of the gestation period (Fig. 1) . In contrast, the NOS 3 expression levels in the PA showed no marked changes through the different stages of development (Fig. 1) . The other NOS isoforms (NOS 1 and NOS 2) were not detected (data not shown).
Effect of metyrapone infusion on NOS 3 mRNA expression level in the fetal DA and corticosterone concentration in the fetal plasma:
The effect of a constant infusion (26.7 g/min) of metyrapone on the NOS 3 mRNA expression level in the DA was observed in the 19.5-day-old fetus; the NOS 3 expression level was much higher at this time point than on the preceding or following days (Fig. 1A) . The NOS 3 mRNA expression level in the DA was not affected after 6 hr of metyrapone infusion but was significantly decreased after 12 hr and 24 hr of continuous infusion when compared to the level in the vehicle-control group (Fig. 2A,   B ). No changes in the NOS 3 mRNA expression level were observed in the DAs of the rats in the vehicle-control group.
The fetal plasma corticosterone concentration significantly decreased in metyrapone-infused rats as compared to the rats of the vehicle-control group. In addition, the extent of this decrease was in good accordance with the changes in the NOS 3 mRNA expression level (Fig. 2C) . Vehicle treatment did not affect the fetal plasma corticosterone concentration throughout the experimental period.
DISCUSSION
In the present study, we showed that the NOS 3 mRNA expression level in the fetal DA was age dependant: NOS 3 mRNA was expressed in the 17.5-day-old fetus; thereafter, its level significantly increased and reached its peak on day 19.5 and then decreased until the end of the gestation period. In contrast, the NOS 3 mRNA expression level in the PA did not change with the developmental stage of the fetus. The trend in the expression pattern of NOS 3 mRNA in the DA was inversely related to the degree of the constrictive effect of the NOS inhibitor, L-LAME, as reported in a previous study [26] . Thus, on the basis of the results of the present study we think that the differential sensitivity of preterm and term DA to NOS inhibitors can be attributed to the agedependant expression of NOS 3 in the DA. It is known that NO readily permeates the biological membrane; further, as NO diffuses into the cytosol, it rapidly binds to the cytosolic guanylate cyclase to form a nitrosyl-heme complex, which activates guanylate cyclase [13, 32] ; this in turn increases the intracellular levels of cyclic guanosine monophosphate (cGMP) [21] . Thus, the signal transduction mechanism involving NO is relatively simple compared with that involving PGE 2 , which requires a membrane-bound receptor to active adenylate cyclase [12] . The present study shows that the age-dependant expression of NOS 3 in the DA reached peak levels during the preterm stage (day 19.5) and decreased until the end of the gestation period. This observation supports the hypothesis that the relatively simple NO-cGMP system is established at a preterm stage and plays a major role during that stage; moreover, a more complex and precise system may play a major role in the advanced stages after the more complex system has developed [26] . In this study, we also showed that the pattern of NOS 3 mRNA expression in the DA was in good agreement with the trends in the plasma corticosterone concentrations in the fetal rats [8] . We also examined the effects of corticosterone on NOS 3 mRNA expression levels in the DA after inhibiting corticosterone synthesis by a constant infusion of metyrapone via an osmotic pump. Our data indicate that continuous metyrapone infusion significantly reduced the NOS 3 mRNA expression level in the fetal DA, which correlated with the reduced fetal plasma corticosterone concentration in a time-dependent manner. The results of the present study suggest that corticosterone concentrations determine the NOS 3 mRNA expression level in the fetal DA. NOS 3 expression is also regulated by a range of transcriptional and posttranscriptional mechanisms. It has been reported that the Nos 3 promoter possesses binding sites for numerous additional transcriptional factors such as activator protein (AP)-1, AP-2, and sterol regulatory cis-elements [16, 34] . Electrophoretic mobility shift assays have revealed that some binding sites are essential for Nos 3 promoter activity, in particular, the sites for the transcription factors specificity protein (Sp) 1 and GATA [28, 30] . Recently, it was found that NOS 3 activity and NO release is regulated by protein-protein interactions with heat shock protein 90 (Hsp90) [10, 22] .
Administration of dexamethasone, a synthetic glucocorticoid, has also been reported to induce vasodilatation in association with increased NOS 3 mRNA levels; further, this vasodilator effect is blocked by L-NAME in rats [1] . The glucocorticoid and glucocorticoid receptor (GR/GC) complex is thought to bind to the glucocorticoid-responsive elements (GREs) located in the promoter region of the target gene, which in turn controls gene transcription. GR/GC also regulates transcription by binding to other transcriptional factors (e.g., AP-1) to regulate gene expression via proteinprotein interaction [31] . Since GREs have not yet been identified in the promoter region of the Nos 3 gene, Bobadilla et al. [1] speculated that increases in the NOS 3 mRNA expression could result from the induction of other transcription factors that act on the promoter region of this isoform gene or from an increase in NOS 3 mRNA stability. A possible explanation could be related to the effect of corticosterone on the heat shock proteins, especially Hsp90, which interacts with NOS 3, resulting in a marked increase in NOS 3 activity and stability. Thus, the increase in the expression of NOS 3 mRNA in the DA was attributable to the increased transcription or stability of NOS 3 mRNA and other mechanisms such as interaction with Hsp90. It is well known that NOS 3 activity is coupled to changes in the endothelial cell Ca 2+ levels, but an increase in Ca 2+ levels alone is not sufficient to affect NOS 3 activity because calmodulin binding and electron flow depend on protein phosphorylation and dephosphorylation [9] . Further research is required to clarify the molecular mechanism of the effect of corticosterone on NOS 3 expression and NOS 3-induced NO production in the premature DA in rats.
In conclusion, the results of the present study indicate that NO is generated by NOS 3 in the premature DA and that the age-dependant expression of NOS 3 in the DA is attributable to corticosterone-associated activity.
